Suggested remit: To appraise the clinical and cost effectiveness of nemolizumab within its marketing authorisation for treating moderate to severe atopic dermatitis in people aged 12 and over.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6221

Provisional Schedule

Committee meeting: 1 05 March 2025
Expected publication 21 May 2025

Project Team

Project lead Jeremy Powell

Email enquiries

External Assessment Group School of Health and Related Research (ScHARR), University of Sheffield

Stakeholders

Companies sponsors Galderma (nemolizumab)
Others Department of Health and Social Care
  NHS England
Patient carer groups Allergy UK
  Changing Faces
  Eczema Outreach Support
  Let’s Face It
  National Eczema Society
  South Asian Health Foundation
  Specialised Healthcare Alliance
Professional groups British Association of Dermatologists
  British Dermatological Nursing Group
  British Geriatrics Society
  British Society for Cutaneous Allergy
  Neonatal and Paediatric Pharmacists Group
  Primary Care Dermatology Society
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Paediatrics and Child Health
  Royal College of Pathologists
  Royal College of Physicians
  Royal Pharmaceutical Society
  Royal Society of Medicine
  St John’s Institute of Dermatology
  UK Clinical Pharmacy Association
Associated public health groups Public Health Wales
  UK Health Security Agency
Comparator companies Abbvie (upadacitinib)
  Advanz Pharma (methotrexate)
  Almirall (lebrikizumab)
  Aspen (azathioprine, mycophenolate mofetil)
  Cipla UK (methotrexate)
  Dexcel pharma (ciclosporin)
  Eli Lilly (baricitinib)
  Hospira (methotrexate)
  LeoLaboratories (tralokinumab)
  Medac (methotrexate)
  Morningside Healthcare (methotrexate)
  Mylan (azathioprine; ciclosporin, mycophenolate mofetil)
  Nordic Pharma (methotrexate)
  Nova (azathioprine; mycophenolate mofetil)
  Novartis Pharmaceuticals (ciclosporin)
  Orion Pharma (methotrexate)
  Pfizer (abrocitinib)
  Rosemont Pharmaceuticals (methotrexate)
  Sandoz (methotrexate)
  Sanofi (dupilumab)
  Santen UK (ciclosporin)
  Strides Pharma (azathioprine, mycophenolate mofetil)
  Tillomed Laboratories (azathioprine, mycophenolate mofetil)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health - Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups Centre of Evidence-based Dermatology, University of Nottingham
  Cochrane Skin Group
  Dermatrust
  Genomics England
  MRC Clinical Trials Unit
  National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
31 July 2024 Invitation to participate
18 June 2024 Please note revised title for ID6221. In addition ID6451 will now run as a separate appraisal on the same timelines. Please see relevant topic webpage for further information
09 May 2024 - 07 June 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6221
09 May 2024 In progress. Scoping commenced.
18 November 2022 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual